 Home > Active Ingredient News > Blood System > JAHA: The use of erythropoietin in hemodialysis patients and the risk of stroke

JAHA: The use of erythropoietin in hemodialysis patients and the risk of stroke

 Last Update: 2021-07-31
 Source: Internet
 Author: User

Tags

diet heart disease diabetes

material study

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Erythropoietin using targeted increase in hemoglobin levels to treat anemia in patients with chronic kidney disease and its heart vessels increased risks associated, including stroke risk

Heart vascular stroke

Recently, a research article was published in JAHA, an authoritative journal in the field of cardiovascular disease.

Researchers used the Cox proportional hazards regression model to estimate the risk ratio (HR) of stroke and its subtypes in erythropoietin-treated patients compared to non-treated patients

Odds ratio analysis result

Compared with non-erythropoietin users, the risk of stroke in erythropoietin users did not increase (adjusted HR 1.

It can be seen that the use of erythropoietin therapy in patients undergoing hemodialysis has nothing to do with the increased risk of stroke or any subtype of stroke

Erythropoietin therapy in patients on hemodialysis is not associated with an increased risk of stroke or any of its subtypes of stroke

Original source:

Peir‐Haur Hung.

Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Dextran powder

CAS No.: 9004-54-0

Pharmacy Grade

$1-1.2/KG FOB

Dextran iron powder

CAS No.: 9004-66-4

Pharmacy Grade

$1-1.3/KG FOB

Clopidogrel

CAS No.: 113665-84-2

Industrial Grade / pharmaceutical grade

$1/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.